Anne V. Salomon
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
ASO Visual Abstract: Impact of Tumor Size on Neoadjuvant Chemotherapy Outcomes in Breast Cancer.
Journal: Annals of surgical oncology
Published: September 03, 2026
Impact of Tumor Size on Neoadjuvant Chemotherapy Outcomes in Breast Cancer.
Journal: Annals of surgical oncology
Published: April 02, 2026
Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.
Journal: The Lancet. Oncology
Published: November 17, 2025
Clinical and pathological features of renal tumours among women previously treated for breast carcinomas - the CanSeRe study.
Journal: The French journal of urology
Published: July 26, 2024
Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 29, 2022
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
Journal: Nature communications
Published: April 14, 2022
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.
Journal: Genome medicine
Published: November 30, 2020
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial.
Journal: NPJ precision oncology
Published: September 24, 2020
Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Journal: Journal of the National Cancer Institute
Published: February 11, 2020
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Journal: Journal of hematology & oncology
Published: September 23, 2019
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Journal: Theranostics
Published: April 29, 2019
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Journal: Science translational medicine
Published: March 12, 2019
Showing 1-12 of 12
Last Updated: 09/26/2026